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Variable airflow limitation can be diagnosed by
spirometry in asthmatic patients or provoked in a
lung function laboratory by getting patients to in-
hale substances that induce bronchoconstriction, so
making it possible to detect and measure the airway
hyperresponsiveness (AHR) frequently associated
with the diagnosis of asthma and its symptoms
[1,2]. The intensity of AHR presents wide variability
in individuals in general and particularly in asth-
matic subjects, where the degree of AHR correlates
with the airway inflammation and the severity of the
disease [3,4].
Airway reactivity can be assessed with either direct
or indirect stimuli. In the former case, methacholine
or histamine, that directly act on airways smooth
muscle, are usually employed [5], while
prostaglandin D2 or leukotrienes are mostly used for
research purposes. The latter (indirect stimuli) in-
clude not only pharmacological agents such as
adenosine monophosphate (AMP) or propranolol,
sulphur dioxide, sodium metabisulphite, ozone,
tachykinins and platelet activating factor (generally
used in research trials), but also physical stimuli
such as exercise, eucapnic hyperpnea of dry air, dis-
tilled water, hypertonic saline, and mannitol. These
indirect stimuli determine airflow limitation by
stimulating inflammatory cells, epithelial cells and
nerves to release mediators that act on specific re-
ceptors of the smooth muscle and induce its con-
traction with resultant airway narrowing, and they
can also determine a microvascular leakage [1,6,7]. 
Mannitol challenge is included in the category of
osmotic aerosols, whose main reference is hyper-
tonic saline, an easy to perform test that causes in-
creased airways osmolarity and delivery of hista-
mine from mast cells; it also shows a good correla-
tion with the level of bronchial inflammation 
[8-10]. Bronchial challenge with inhalation of man-
nitol dry powder is not very new, since it was intro-
duced in 1997 by Anderson and coworkers [11];
nevertheless it is not so widely used as the direct
challenges with methacholine or histamine. 
Bronchial challenge with directly stimulating agents
shows high sensitivity for diagnosing asthma due to
the high negative predictive value, while it has low
specificity to distinguish between asthmatic and
normal subjects or patients affected with chronic
airflow limitation [6]. 
On the contrary, physical stimuli are more specific
than methacholine or histamine to distinguish be-
tween asthmatic and normal subjects, but their sen-
sitivity is relatively low compared with direct agents
[12-14]. Thus, the direct challenges are the choice
method to exclude current asthma, whereas the in-
direct ones are indicated to confirm the presence of
asthma, especially when it is induced by exercise
[15]. 
Mannitol shows a good correlation with other indi-
rect stimuli such as exercise, hypertonic solutions
and eucapnic hyperventilation [11,16] and it is not
limited by physiologic factors as are other indirect
challenges, namely exercise and eucapnic hyper-
ventilation [6]. Mannitol test has also shown similar
effects as AMP challenge; thus the two tests are to
some extent interchangeable [17]. 
When given as a dry powder, mannitol increases
the osmolarity of the bronchial mucosa that in turn
causes the release from mastcells and also from
eosinophils of histamine, prostaglandins and
leukotrienes both in asthmatics and, to a much less-
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er degree, in normal subjects [18-20]. Furthermore,
a correlation has been found between the level of
bronchial hyperresponsiveness revealed by the
mannitol challenge and the amount of eosinophils
in sputum of asthmatic patients not treated with in-
haled steroids [21]. 
The technique of mannitol bronchial challenge is
very easy to perform, safe and less time consuming
than other indirect tests, and it consists in delivering
increasing doses of the osmotic substance through a
dry-powder inhaler, recording the FEV1 value 1
minute after each inhalation. The response is con-
sidered positive when a 15% fall in FEV1 compared
to baseline is obtained after inhaling a cumulative
dose (PD15) of mannitol of 635 mg or less
[11,22,23]. This technique also allows to collect
bronchial secretions (that increase when mannitol is
administered), which can be examined for the pres-
ence of inflammatory cells [24]. 
So, what is the rationale for using mannitol in
bronchial challenges? 
The main usefulness of the challenge with mannitol
is that it allows, in patients who have current symp-
toms of asthma, to confirm or exclude the presence
of the disease, whereas a negative methacholine re-
sult is particularly valuable to rule out a diagnosis of
asthma. Furthermore, the mannitol test seems par-
ticularly useful in patients affected with active asth-
ma, where a high level of hyperreactivity as re-
vealed by mannitol PD15 is evidence of current air-
way inflammation, which highlights the need for
treatment able to counteract inflammatory cells and
their mediators, e.g. inhaled steroids, antihistaminic
and anti-leukotrienes compounds. However, it
should be borne in mind that the mannitol chal-
lenge, as other indirect and direct stimuli, fails to
confirm asthma in about 30% of subjects with mild
symptoms and bronchial inflammation; in some of
these patients other diagnoses must be investigated
[7,23]. Nevertheless, the mannitol challenge ap-
pears a valuable method to monitor the inflamma-
tion and the outcome of the disease in asthmatic
patients during treatment with antinflammatory
drugs. It may also be useful in a work or occupa-
tional setting to reveal possible sensitization to pro-
fessional agents, and in athletes that present airway
hyperresponsiveness after strenuous exercise, to
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